A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Clinical trial NCT05114603 · UNKNOWN

Trial details

NCT number: NCT05114603
Sponsor: Shanghai Henlius Biotech
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Melanoma

Start date: 2022-03-21
Primary completion: 2023-08-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.